SuperworthAllogene Therapeutics revenue ALLO
Sales by quarter and over the last twelve months, from 2020.
- Last 12 months, to Jun 30, 2026
- n/m
- a quarter missing
- Latest quarter, Q2 FY26
- $4.6M
- Fiscal year 2025
- $0
- −100% on the year before
Allogene Therapeutics' twelve-month revenue can't be added up yet: a quarter of its results is missing from our data.
In its latest quarter, Q2 FY26, it was $4.6M.
Revenue over time
Fiscal year by fiscal year
| Fiscal year | Revenue | Change |
|---|---|---|
| FY2025 | $0 | −100% |
| FY2024 | $22K | −77% |
| FY2023 | $95K | −57% |
| FY2022 | $222K | −99% |
| FY2021 | $38.5M | n/a |
| FY2020 | $0 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | Revenue | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $4.6M | n/a | n/a | |
| Q4 FY25 | $0 | n/a | $0 | |
| Q3 FY25 | $0 | n/a | $0 | |
| Q2 FY25 | $0 | n/a | $0 | |
| Q1 FY25 | $0 | −100% | $0 | |
| Q4 FY24 | $0 | −100% | $22K | |
| Q3 FY24 | $0 | −100% | $43K | |
| Q2 FY24 | $0 | −100% | $65K | |
| Q1 FY24 | $22K | −27% | $87K | |
| Q4 FY23 | $21K | −19% | $95K | |
| Q3 FY23 | $22K | −55% | $100K | |
| Q2 FY23 | $22K | −74% | $127K |
Against its peers
Companies in Biotechnology nearest Allogene Therapeutics' size, closest first, today.
| Company | Revenue, 12 months | Growth |
|---|---|---|
| ALLOAllogene Therapeutics | n/m | |
| MGTXMeiraGTx | $397.5M | |
| PLXProtalix BioTherapeutics | $80.6M | +30% a year |
| VCELVericel | $306.3M | +23% a year |
| ADMAAdma Biologics | $512.3M | +8% a year |
| Peer median | $351.9M |
What the revenue tells you
Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.
Growing revenue with shrinking margins is a warning, not a win.
More on Allogene Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.